- Home
- OBAI vs RLYB Comparison
OBAI vs RLYB Comparison
Compare OBAI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBAI | RLYB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 28.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OBAI | RLYB |
|---|---|---|
| Price | $1.43 | $8.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 543.4K | 254.4K |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $1.30 | $0.22 |
| 52 Week High | $19.95 | $11.49 |
Technical Indicators
Market Signals| Indicator | OBAI | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 9.26 | 56.01 |
| Support Level | N/A | $0.48 |
| Resistance Level | $2.15 | $11.49 |
| Average True Range (ATR) | 0.21 | 0.68 |
| MACD | 0.41 | -0.43 |
| Stochastic Oscillator | 11.76 | 0.00 |
Price Performance
Historical ComparisonAbout OBAI TG-17 Inc. Common Stock
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.